Esperion Therapeutics Long Term Debt

As of the most recent data (March 2026), ESPR shows a long-term debt of $250M. That compares with $240M in the prior-year period — up 4.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ESPR's long-term debt is now $250M (was $240M) — a 4.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Esperion Therapeutics is outperforming or lagging.

Tracking ESPR's long-term debt over time shows whether Esperion Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $250M That compares with $240M in the prior-year period — up 4.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Esperion Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $250M) with ownership activity and broader fundamentals.

Esperion Therapeutics's long-term debt is $250M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.